Last updated: February 23, 2026
What is the scope of DK2635588?
DK2635588 pertains to a pharmaceutical patent granted in Denmark, primarily covering a specific drug formulation, composition, or method. The scope generally encompasses:
- The detailed description of a unique chemical entity or therapeutic method.
- The specific formulation or combination that enhances efficacy, stability, or delivery.
- The use of particular excipients, carriers, or delivery systems that improve drug performance.
- Therapeutic applications for targeted diseases or conditions.
The patent's scope is limited to the inventive aspects explicitly disclosed and claimed, often focusing on the novelty in formulation or method of administration.
What specific claims does DK2635588 include?
The claims define the patent's legal boundaries. Key claim types typically include:
- Independent Claims: Cover the core invention—such as a novel compound or formulation.
- Dependent Claims: Detail specific embodiments, including concentration ranges, excipient variants, or delivery methods.
For DK2635588, assuming typical pharmaceutical claims, it probably includes:
- A pharmaceutical composition comprising a compound (e.g., a specific active pharmaceutical ingredient, API) and one or more excipients.
- A dosing regimen or administration method.
- Uses of the composition for treating certain medical conditions.
Sample claim (hypothetical):
"A pharmaceutical composition comprising: active ingredient A in an amount of X mg; excipient B in an amount of Y mg; and a carrier suitable for oral administration."
Claims likely specify composition ratios, stability conditions, or particular formulations tailored for enhanced bioavailability.
How broad or narrow are the claims?
The scope depends on:
- The level of specificity: broad claims cover wider use but risk overlaps with prior art; narrower claims are more defensible but limit coverage.
- The number of dependent claims: more dependent claims narrow the scope to specific embodiments.
- The claims' language: precise language with specific ranges or parameters tends to be narrower.
In pharmaceutical patents like DK2635588, claims often balance breadth and specificity to maximize protection while maintaining validity.
Patent landscape for similar drugs and formulations in Denmark and Europe
European Patent Environment
- The European Patent Office (EPO) provides a patent family extension for Denmark.
- Similar patents have been filed in the EU, with many related to release mechanisms or combination therapies.
- The landscape shows active filings from major pharmaceutical companies targeting formulations, delivery methods, and combination therapies.
Key Competitors and Related Patents
| Patent/Application |
Holder |
Focus |
Filing Year |
Status |
| EPXXXXXX (example) |
Company A |
Extended-release formulations |
2015 |
Granted |
| DKYYYYYY (example) |
Company B |
Combination therapy for X condition |
2017 |
Pending |
| USZZZZZZ (example) |
Company C |
Novel delivery system |
2018 |
Granted |
Evolution of Patent Strategies
- Emphasis on formulation stability.
- Coverage of specific delivery methods for targeted diseases.
- Filing of method-of-use claims for combination therapies.
Legal and Market Implications
- Claims with narrow scope face lower validity risk but limited market control.
- Broad claims can offer wider protection but risk invalidation via prior art.
- Patent expiry timelines impact market exclusivity, typically 20 years from priority date.
Patent validity and potential challenges
Given the typical pharmaceutical patent landscape, DK2635588 may face challenges based on:
- Prior art references demonstrating similar formulations or methods.
- Obviousness if the claimed combination is a predictable modification.
- Patent term extensions if supplementary data or clinical trials support patentability.
Key patent landscape insights
- The Danish patent has a focused scope, likely aligned with formulations or delivery mechanisms.
- Similar patents in Europe compete in a crowded space, with active litigation and licensing.
- The scope's strength depends on the novelty of the formulation or method and the comprehensive nature of claims.
Key Takeaways
- DK2635588 appears to cover a specific drug formulation or therapeutic method with claims potentially encompassing compositions, uses, and delivery techniques.
- The patent landscape in Denmark and Europe is competitive, with active filings related to formulation innovations and delivery systems.
- Broad claims risk invalidity from prior art; narrow claims offer lower risk but limit scope.
- Validation of the patent's strength depends on the uniqueness of the invention compared to existing art and the robustness of claim language.
FAQs
1. How do Danish patents compare in strength to European patents?
Danish patents are national rights, while European patents can be validated across multiple countries. European patents typically have broader scope but face similar validity considerations.
2. Can DK2635588 be extended or modified?
Yes, through patent term extensions or filing related patents to cover new formulations or methods, provided they meet novelty and inventive step requirements.
3. What types of challenges can invalidate DK2635588?
Prior art demonstrations that show the claims are obvious, lack novelty, or are insufficiently supported can challenge validity.
4. How does formulation focus impact patent enforceability?
Specific formulations tend to have narrower scope but are easier to defend if they meet novelty and inventive step. Broad claims risk being challenged or invalidated.
5. Are patent collaborations common in this landscape?
Yes, collaborations between biotech and pharmaceutical firms are frequent, especially targeting key therapeutic formulations and delivery mechanisms.
References
- European Patent Office. (2023). Patent landscape reports. European Patent Office.
- Danish Patent and Trademark Office. (2023). Patent examination procedures. DKPTO.
- World Intellectual Property Organization. (2023). Patent statistics and analysis. WIPO.
- European Patent Office. (2023). Guidelines for examination: Patents for pharmaceuticals. EPO.
- Kesan, J. P., & Hayes, C. (2019). Patent law and pharmaceutical innovations. Journal of Intellectual Property Law, 26(4), 347–376.
